• Skip to main content
  • Skip to footer
  • Careers
  • Contact

Abzyme Therapeutic

Impacting the research, diagnosis and treatment of human diseases through our novel antibody discovery and optimization platform

  • Company
    • About
    • Strategy
    • Management Team
    • Investors
  • Technology
    • Overview
    • SDALibTM Ab Generation
    • SDALibTM Ab Optimization
    • Abz2TM Bispecific
  • Pipeline
    • Overview
    • Available Modular Antibodies
    • Partnering
  • Media & Publications
    • Press Releases
    • Events & Presentations
    • Publications by Abzyme Scientists

Main Content

  • In vivo antigen-directed antibody affinity maturation: Mimicking mammalian antibody diversification & affinity maturation processes. >>
  • Novel triple-mode platform for in vivo antibody maturation, surface display and secretion. READ MORE >>
  • Single domain antibody: ideal building block to generate multi-specific antibody molecules. READ MORE>>
  • Abz2 bispecifics: Well-expressing multi-function full-length antibody with a completely normal IgG structure. READ MORE >>
  • Ideal platform for generation of antibodies against non-immunogenic and cell surface antigens. READ MORE>>
  • Advanced antibody optimization capabilities to produce best-in-class therapeutic candidates. READ MORE>>
  • Eukaryotic-based in vitro selection system: Filters for well-expressing and manufacturable antibody candidates. READ MORE>>
Impacting the treatment of human disease through domain antibody technologies

Footer

© Abzyme Therapeutics, LLC. All Rights Reserved.

321 Jones Blvd, Royersford, PA 19468
610-990-7531 | [email protected]